Belinostat

Summary

Belinostat (CHEMBL408513) is an approved small-molecule antineoplastic agent (ATC L01XH04) targeting HDAC2, HDAC3, and HDAC6; indicated across 39 conditions including peripheral t-cell lymphoma, not otherwise specified and neoplasm; with CIViC clinical evidence for 2 variant-indication associations (e.g. UGT1A1 UGT1A1*28 in cancer).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01XH04
• Targets: 9 (HDAC2, HDAC3, HDAC6…)
• Indications: 39 conditions
• Clinical trials: 54
• Precision-oncology evidence (CIViC): 2 variant–indication associations
• Chemistry: 318.3 Da · C15H14N2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL408513
Name	Belinostat
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6918638
ChEBI	CHEBI:61076
ATC	L01XH04
Molecular formula	C15H14N2O4S
Molecular weight	318.3
InChIKey	NCNRHFGMJRPRSK-MDZDMXLPSA-N

SMILES: C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO

IUPAC name: (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide

ChEBI definition: A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.

Pharmacological roles (ChEBI): antineoplastic agent, EC 3.5.1.98 (histone deacetylase) inhibitor.

Also known as: Beleodaq, Belinostat, NSC-726630, NSC726630, PX-105684, PXD-101, PXD101, belinostat, BELINOSTAT, Belinosta, BELINOSTAT (PXD101), BelinostatÊ

Patent coverage: 3,320 distinct patent families (7,765 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,545 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HDAC2	histone deacetylase 2	Inhibition	6.9	3.1%	Q92769
HDAC3	histone deacetylase 3	Inhibition	7.52	95.1% (common-essential)	O15379
HDAC6	histone deacetylase 6	Inhibition	7.09	0%	Q9UBN7
HDAC8	histone deacetylase 8	Inhibition	6.67	4.9%	Q9BY41
HDAC9	histone deacetylase 9	Inhibition	6.6	0%	Q9UKV0
HDAC1	histone deacetylase 1	Inhibition	7.39	4.5%	Q13547
HDAC4	histone deacetylase 4	Inhibition	6.42	3.1%	P56524
HDAC5	histone deacetylase 5	Inhibition	6.76	0.5%	Q9UQL6
HDAC7	histone deacetylase 7	Inhibition	7.12	4.2%	Q8WUI4

Broader ChEMBL bioactivity targets: 22 (assay-derived). Sample: Bromodomain-containing protein 4, Histone deacetylase 3, Protein deacetylase HDAC6, Histone deacetylase 2, Estrogen receptor, Histone deacetylase, Histone deacetylase (HDAC1 and HDAC2), Prostaglandin G/H synthase 1, 3’,5’-cyclic-AMP phosphodiesterase 4A, Histone deacetylase 5.

Bioactivity

ChEMBL activities: 123 potent at pChembl ≥ 5 of 126 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HDAC1	9.07	Ki	0.85	nM	CHEMBL_ACT_3389987
HDAC2	9.07	Ki	0.85	nM	CHEMBL_ACT_3389988
HDAC2	9.05	Ki	0.9	nM	CHEMBL_ACT_15656397
HDAC1	9.05	Ki	0.9	nM	CHEMBL_ACT_15656408
HDAC1	8.86	IC50	1.38	nM	CHEMBL_ACT_19490103
HDAC3	8.82	Ki	1.5	nM	CHEMBL_ACT_15656387
HDAC3	8.82	Ki	1.5	nM	CHEMBL_ACT_3389989
HDAC6	8.8	Ki	1.6	nM	CHEMBL_ACT_15656466
HDAC6	8.8	Ki	1.6	nM	CHEMBL_ACT_3389992
PIK3CA	8.54	IC50	2.9	nM	CHEMBL_ACT_29106232
HDAC3	8.14	IC50	7.3	nM	CHEMBL_ACT_23190614
HDAC3	8.05	IC50	9	nM	CHEMBL_ACT_25965411
HDAC6	8.01	IC50	9.85	nM	CHEMBL_ACT_18095238
HDAC3	8	IC50	10	nM	CHEMBL_ACT_18998619
HDAC6	8	IC50	10	nM	CHEMBL_ACT_25992109
HDAC6	8	IC50	10	nM	CHEMBL_ACT_26150523
HDAC6	8	Ki	10	nM	CHEMBL_ACT_6371585
HDAC1	7.89	IC50	13	nM	CHEMBL_ACT_25965424
HDAC6	7.85	IC50	14	nM	CHEMBL_ACT_25965420
HDAC6	7.82	IC50	15	nM	CHEMBL_ACT_2118155
HDAC6	7.82	IC50	15	nM	CHEMBL_ACT_24982164
HDAC4	7.82	IC50	15	nM	CHEMBL_ACT_25992101
HDAC4	7.82	IC50	15	nM	CHEMBL_ACT_26150518
HDAC1	7.82	IC50	15	nM	CHEMBL_ACT_6302326
HDAC4	7.82	Ki	15	nM	CHEMBL_ACT_6371557
HDAC1	7.75	IC50	18	nM	CHEMBL_ACT_2118125
HDAC1	7.75	IC50	18	nM	CHEMBL_ACT_24982137
HDAC3	7.72	IC50	19	nM	CHEMBL_ACT_25992093
HDAC3	7.72	IC50	19	nM	CHEMBL_ACT_26150513
HDAC3	7.72	Ki	19	nM	CHEMBL_ACT_6370678

Target pathways

Aggregated over 9 target gene(s): HDAC2, HDAC3, HDAC6, HDAC8, HDAC9, HDAC1, HDAC4, HDAC5, HDAC7.

Top Reactome pathways

71 total, by targets touching each:

Pathway	Targets	Genes
NOTCH1 Intracellular Domain Regulates Transcription	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Constitutive Signaling by NOTCH1 PEST Domain Mutants	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Notch-HLH transcription pathway	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Regulation of PTEN gene transcription	5	HDAC1, HDAC2, HDAC3, HDAC5, HDAC7
HDACs deacetylate histones	4	HDAC1, HDAC2, HDAC3, HDAC8
p75NTR negatively regulates cell cycle via SC1	3	HDAC1, HDAC2, HDAC3
SUMOylation of chromatin organization proteins	3	HDAC1, HDAC2, HDAC4
Regulation of MECP2 expression and activity	3	HDAC1, HDAC2, HDAC3
STAT3 nuclear events downstream of ALK signaling	3	HDAC1, HDAC2, HDAC3
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression	2	HDAC1, HDAC2
NoRC negatively regulates rRNA expression	2	HDAC1, HDAC2
Regulation of TP53 Activity through Acetylation	2	HDAC1, HDAC2
RNA Polymerase I Transcription Initiation	2	HDAC1, HDAC2
RUNX2 regulates osteoblast differentiation	2	HDAC3, HDAC6
MECP2 regulates neuronal receptors and channels	2	HDAC1, HDAC2
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	2	HDAC1, HDAC2
Potential therapeutics for SARS	2	HDAC1, HDAC2
Negative Regulation of CDH1 Gene Transcription	2	HDAC1, HDAC2
Factors involved in megakaryocyte development and platelet production	2	HDAC1, HDAC2
Regulation of endogenous retroelements by KRAB-ZFP proteins	2	HDAC1, HDAC2
Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	2	HDAC1, HDAC2
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	2	HDAC1, HDAC2
NuRD complex assembly	2	HDAC1, HDAC2
Interaction of NuRD complexes with transcription factors	2	HDAC1, HDAC2
Transcription of E2F targets under negative control by DREAM complex	1	HDAC1
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	1	HDAC1
G0 and Early G1	1	HDAC1
PPARA activates gene expression	1	HDAC3

Dominant GO biological processes

GO term	Targets
chromatin organization	9
negative regulation of transcription by RNA polymerase II	8
negative regulation of DNA-templated transcription	8
positive regulation of transcription by RNA polymerase II	5
protein deacetylation	5
epigenetic regulation of gene expression	5
negative regulation of gene expression, epigenetic	5
negative regulation of macromolecule biosynthetic process	4
chromatin remodeling	3
positive regulation of cell population proliferation	3
response to xenobiotic stimulus	3
heterochromatin formation	3
circadian regulation of gene expression	3
positive regulation of intracellular estrogen receptor signaling pathway	3
negative regulation of apoptotic process	3

Indications & clinical

Indications

39 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peripheral T-cell lymphoma, not otherwise specified	4	MONDO:0004964	EFO:0000211
neoplasm	4	MONDO:0005070	EFO:0000616
mature T-cell and NK-cell non-Hodgkin lymphoma	4	MONDO:0000430	MONDO:0000430
T-cell non-Hodgkin lymphoma	4	MONDO:0015760	MONDO:0015760
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
mesothelioma	2	MONDO:0005065	EFO:0000588
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
Burkitt lymphoma	2	MONDO:0007243	EFO:0000309
carcinoma	2	MONDO:0004993	EFO:0000313
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
glioblastoma	2	MONDO:0018177	EFO:0000519
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
primary cutaneous T-cell non-Hodgkin lymphoma	2	MONDO:0000607	EFO:0002913
mantle cell lymphoma	2	MONDO:0018876	EFO:1001469
endometrioid adenocarcinoma	2	MONDO:0005026	EFO:0000466
anaplastic large cell lymphoma	2	MONDO:0020325	EFO:0003032
thymic carcinoma	2	MONDO:0006451	EFO:1000576
thymoma	2	MONDO:0006456	EFO:1000581
ovarian serous cystadenocarcinoma	2	MONDO:0006046	EFO:1000043
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
non-Hodgkin lymphoma	2	MONDO:0018908	EFO:0005952
uveal melanoma	2	MONDO:0006486	EFO:1000616
lymphoma	1	MONDO:0005062	EFO:0000574
lymphoid neoplasm	1	MONDO:0005157	EFO:0001642
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
Hodgkins lymphoma	1	MONDO:0004952	EFO:0000183
mycosis fungoides	1	MONDO:0009691	EFO:1001051
adenocarcinoma	1	MONDO:0004970	EFO:0000228
blast phase chronic myelogenous leukemia, BCR-ABL1 positive	1	MONDO:0006115	EFO:1000131
soft tissue sarcoma	1	MONDO:0018078	EFO:1001968
follicular lymphoma	1	MONDO:0018906	MONDO:0018906
small cell lung carcinoma	1	MONDO:0008433	EFO:0000702
urothelial carcinoma	1	MONDO:0040679	EFO:0008528
leukemia	1	MONDO:0005059	EFO:0000565

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 54.

Phase distribution

Phase	Trials
PHASE1	25
PHASE2	19
PHASE1/PHASE2	7
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06072131	PHASE3	RECRUITING	To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
NCT06561048	PHASE3	RECRUITING	Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT07234162	PHASE3	RECRUITING	A Phase 3 Multinational Study of Golidocitinib Versus Investigator’s Choice in r/r PTCL (JACKPOT19)
NCT04340843	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
NCT04747236	PHASE2	RECRUITING	Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator’s Choice in PTCL
NCT05170334	PHASE2	ACTIVE_NOT_RECRUITING	Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
NCT06406465	PHASE2	RECRUITING	A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
NCT00131261	PHASE2	COMPLETED	Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
NCT00274651	PHASE2	TERMINATED	A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
NCT00301756	PHASE2	COMPLETED	Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
NCT00303953	PHASE2	COMPLETED	PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
NCT00321594	PHASE1/PHASE2	COMPLETED	Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
NCT00357032	PHASE2	COMPLETED	PXD101 in Treating Patients With Acute Myeloid Leukemia
NCT00357162	PHASE2	COMPLETED	Belinostat in Treating Patients With Myelodysplastic Syndromes
NCT00365053	PHASE2	COMPLETED	PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
NCT00421889	PHASE1/PHASE2	COMPLETED	A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
NCT00431340	PHASE2	TERMINATED	A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
NCT00589290	PHASE2	COMPLETED	Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
NCT00865969	PHASE2	COMPLETED	Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT00873119	PHASE2	COMPLETED	Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
NCT00878722	PHASE1/PHASE2	COMPLETED	Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
NCT00878800	PHASE1/PHASE2	COMPLETED	A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
NCT00993616	PHASE2	COMPLETED	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
NCT01188707	PHASE1/PHASE2	TERMINATED	A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
NCT01310244	PHASE1/PHASE2	COMPLETED	MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
NCT01686165	PHASE2	COMPLETED	Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
NCT02137759	PHASE2	UNKNOWN	MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
NCT02701673	PHASE1/PHASE2	WITHDRAWN	Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
NCT02737046	PHASE2	COMPLETED	Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
NCT04315233	PHASE1	RECRUITING	Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT05154994	PHASE1	ACTIVE_NOT_RECRUITING	Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
NCT05627245	PHASE1	ACTIVE_NOT_RECRUITING	Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
NCT00334789	PHASE1	COMPLETED	Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
NCT00348985	PHASE1	COMPLETED	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00351975	PHASE1	COMPLETED	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
NCT00354185	PHASE1	TERMINATED	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
NCT00413075	PHASE1	COMPLETED	Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
NCT00413322	PHASE1	COMPLETED	Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
NCT00926640	PHASE1	COMPLETED	A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
NCT01075425	PHASE1	COMPLETED	Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

Clinical evidence (CIViC)

Variant × indication × effect (2 predictive associations from 2 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
UGT1A1 UGT1A1*28	Cancer	Adverse Response	Belinostat	CIViC A	EID1792
UGT1A1 UGT1A1*60	Cancer	Adverse Response	Belinostat	CIViC B	EID1795

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 7 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

96 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
CELECOXIB	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
GIVINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
PANOBINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
PHENYLBUTANOIC ACID	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
ROMIDEPSIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
SODIUM PHENYLBUTYRATE	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
VORINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
ABEXINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
CAFFEIC ACID	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
CURCUMIN	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
ENTINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
PRACINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
TACEDINALINE	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
TUCIDINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
AR-42	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
CHLOROGENIC ACID	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
DACINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
FIMEPINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
NANATINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
QUISINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Pazopanib	PubChem	Approved	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
RICOLINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8
BENDAMUSTINE	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC8
TINOSTAMUSTINE	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC8
CITARINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC6, HDAC7, HDAC8
BORTEZOMIB	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
MOCETINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
EBSELEN	ChEMBL	Phase 3	HDAC2, HDAC5, HDAC6, HDAC9
BUTYRIC ACID	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC8
DOMATINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC9
SODIUM BUTYRATE	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC8
ATORVASTATIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC6
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC6, HDAC8
LOVASTATIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC6
BAICALEIN	ChEMBL	Phase 2	HDAC1, HDAC6, HDAC8
.gamma.-aminobutyric acid	PubChem	Approved	HDAC5, HDAC7, HDAC9
acetylcysteine	PubChem	Approved	HDAC5, HDAC7, HDAC9
Crizotinib	PubChem	Approved	HDAC1, HDAC2, HDAC6
VALPROIC ACID	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2
MOLIBRESIB	ChEMBL	Phase 2	HDAC1, HDAC2
NICOXAMAT	ChEMBL	Phase 2	HDAC1, HDAC6
RESMINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC6
Gefitinib	PubChem	Approved	HDAC5, HDAC9
Idelalisib	PubChem	Approved	HDAC1, HDAC6
ABAMETAPIR	ChEMBL	Phase 4 (approved)	HDAC6
ATALUREN	ChEMBL	Phase 4 (approved)	HDAC6
AXITINIB	ChEMBL	Phase 4 (approved)	HDAC6
BUFEXAMAC	ChEMBL	Phase 4 (approved)	HDAC6
EVANS BLUE FREE ACID	ChEMBL	Phase 4 (approved)	HDAC6
EXIFONE	ChEMBL	Phase 4 (approved)	HDAC1
FEBUXOSTAT	ChEMBL	Phase 4 (approved)	HDAC6
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	HDAC6
GENTIAN VIOLET	ChEMBL	Phase 4 (approved)	HDAC6
INDOPROFEN	ChEMBL	Phase 4 (approved)	HDAC6
MARIBAVIR	ChEMBL	Phase 4 (approved)	HDAC6
MOMELOTINIB	ChEMBL	Phase 4 (approved)	HDAC1
MONOBENZONE	ChEMBL	Phase 4 (approved)	HDAC6
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	HDAC6
PHENYL AMINOSALICYLATE	ChEMBL	Phase 4 (approved)	HDAC6
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	HDAC6